An animal model showed that a neutralizing antibody against FGF19 was able to abrogate liver cancer development in transgenic mice and inhibited xenograft tumors from HCC and colon cancer, suggesting feasibility of FGF19 as a therapeutic target (Desnoyers et al., 2008; French et al., 2012). Here, FGF19 is linked to colonic neoplasm.